Skip to main content
HCPCS J9260 · Level II · Part B drug

J9260: methotrexate sodium, HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J9260

Billing unit
50 MG
Inj methotrexate sodium 50mg
ASP payment limit
$2.909
October 2026; -1.1% vs July 2026
Practitioner MUE
400
MAI 3
OPPS status
SI N
NCCI exposure
no PTP pairs
Coverage articles
1
4 states

TL;DR

HCPCS J9260 is the Level II code for Injection, methotrexate sodium, 50 mg, billed per 50 MG. The Medicare Part B ASP payment limit for October 2026 is $2.909 per billing unit, down 1.1% from July 2026. The practitioner MUE allows up to 400 units per date of service (MAI 3), so a full 400-unit day is $1,163.60 at the current limit. Under OPPS it carries status indicator N. J9260 is billed in units of 50 MG; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. Other HCPCS codes whose descriptor names methotrexate: J8612 (Xatmep from Azurity Pharmaceuticals, Inc.; oral route; billed per 2.5 mg); J8611 (Jylamvo from Shorla Oncology Inc.; oral route; billed per 2.5 mg). The ASP crosswalk maps 18 NDCs to it, sold as Methotrexate Sodium by Hikma Pharmaceuticals USA Inc., Teva Parenteral Medicines, Inc., ACCORD HEALTHCARE INC. 1 Medicare coverage article lists the code across 4 states, including A55639.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J9260 at $2.909 per 50 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $2.941 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J9260
QuarterPayment limitPerCoinsurance
October 2026$2.90950 MG20%
July 2026$2.94150 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 18 NDCs from 6 labelers to J9260. Report the NDC in the claim's drug segment and bill the number of J9260 units that equals the quantity administered divided by 50 MG; the last column gives units per full package.

NDCs that crosswalk to J9260
NDCDrug nameLabelerPackage sizeBilling units / package
00143-9367-01Methotrexate SodiumHikma Pharmaceuticals USA Inc.1 × 120
00143-9519-10Methotrexate SodiumHikma Pharmaceuticals USA Inc.2 × 1010
00143-9830-01Methotrexate SodiumHikma Pharmaceuticals USA Inc.1 × 120
00703-3671-01Methotrexate SodiumTeva Parenteral Medicines, Inc.2 × 11
00703-3675-01Methotrexate SodiumTeva Parenteral Medicines, Inc.10 × 15
00703-3678-01Methotrexate SodiumTeva Parenteral Medicines, Inc.40 × 120
00703-3678-81Methotrexate SodiumTeva Parenteral Medicines, Inc.40 × 120
16729-0277-03Methotrexate SodiumACCORD HEALTHCARE INC10 × 15
16729-0277-30Methotrexate SodiumAccord Healthcare Inc2 × 11
16729-0277-35Methotrexate SodiumAccord Healthcare Inc40 × 120
61703-0124-40Methotrexate SodiumPfizer Inc40 × 120
61703-0161-05Methotrexate SodiumPfizer Inc2 × 55
61703-0350-10Methotrexate SodiumPfizer Inc2 × 55
61703-0350-38Methotrexate SodiumPfizer Inc2 × 55
61703-0408-25Methotrexate SodiumPfizer Inc40 × 120
61703-0408-41Methotrexate SodiumPfizer Inc40 × 120
63323-0122-50Methotrexate SodiumFreseniUS Kabi USA, LLC1 × 120
63323-0123-10Methotrexate SodiumFreseniUS Kabi USA, LLC10 × 15

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J9260. For practitioners the limit is 400 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J9260 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services4003 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital4003 Date of Service Edit: ClinicalPrescribing Information
DME supplier4003 Date of Service Edit: ClinicalPrescribing Information

MUE for J9260 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J9260 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J9260 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J9260 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

1 current Medicare Administrative Contractor article lists J9260 in their HCPCS tables, covering 4 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing J9260
ArticleTitleContractor(s)StatesRelated LCD
A55639Billing and Coding: Chemotherapy Agents for Non-Oncologic ConditionsWisconsin Physicians Service Insurance CorporationIA KS MO NEL37205

Diagnoses Medicare contractors cover for J9260

One billing and coding article attaches a covered diagnosis list to J9260: 299 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for J9260
ICD-10-CMDescription (FY2027)Articles covering
J84.111Idiopathic interstitial pneumonia, not otherwise specified1 of 1
J84.112Idiopathic pulmonary fibrosis1 of 1
J84.113Idiopathic non-specific interstitial pneumonitis1 of 1
J84.114Acute interstitial pneumonitis1 of 1
J84.115Respiratory bronchiolitis interstitial lung disease1 of 1
J84.116Cryptogenic organizing pneumonia1 of 1
J84.117Desquamative interstitial pneumonia1 of 1
J84.170Interstitial lung disease with progressive fibrotic phenotype in diseases classified elsewhere1 of 1
J84.178Other interstitial pulmonary diseases with fibrosis in diseases classified elsewhere1 of 1
L12.0Bullous pemphigoid1 of 1
L12.8Other pemphigoid1 of 1
L40.0Psoriasis vulgaris1 of 1
L40.1Generalized pustular psoriasis1 of 1
L40.2Acrodermatitis continua1 of 1
L40.3Pustulosis palmaris et plantaris1 of 1
284 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J9260 are counted here: a group whose instructions name J9260, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to J9260, by article
ArticleContractorGroups that applyCovered codes for J9260Full list
A55639Wisconsin Physicians Service Insurance Corporationgroup 2 applies to J9260299On LCD L37205

Local coverage policies that list J9260

1 active Local Coverage Determination lists J9260 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

  • L37205 Chemotherapy Drugs and their Adjuncts · Wisconsin Physicians Service Insurance Corporation

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J9260 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J9260 carries payment indicator N1, which CMS defines as "Packaged service/item; no separate payment made". An N1 drug is packaged in the ASC: the facility receives no separate payment because the surgical procedure's rate already includes it.

Common denials for J9260 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J9260

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J9260

What does HCPCS code J9260 describe?

J9260 is defined by CMS as "Injection, methotrexate sodium, 50 mg". Each billing unit represents 50 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J9260 a CPT code?

No. J9260 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as methotrexate sodium; CPT codes are five-character codes maintained by the AMA. On a Part B claim J9260 reports the drug itself in 50 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J9260 in October 2026?

The ASP-based payment limit is $2.909 per 50 MG, with 20% beneficiary coinsurance. The July 2026 limit was $2.941. Commercial payers use their own fee schedules.

How many units of J9260 can be billed per day?

The practitioner Medically Unlikely Edit is 400 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J9260?

The October 2026 ASP crosswalk lists 18 NDCs from 6 labelers: Methotrexate Sodium (Hikma Pharmaceuticals USA Inc.); Methotrexate Sodium (Teva Parenteral Medicines, Inc.); Methotrexate Sodium (ACCORD HEALTHCARE INC); Methotrexate Sodium (Accord Healthcare Inc). For example NDC 00143-9367-01 (package size 1) equals 20 billing units of J9260.

Does J9260 have NCCI bundling edits?

No active practitioner PTP pairs list J9260 as a column-1 or column-2 code in the v323r0 release.

J9260 vs J8612: what is the difference?

Both are HCPCS Level II codes whose descriptor names methotrexate. What sets J8612 apart: Xatmep from Azurity Pharmaceuticals, Inc.; oral route; billed per 2.5 mg. J9260 is billed per 50 mg, limit $2.909, MUE 400; J8612 is billed per 2.5 mg, limit $22.855. Report the code whose descriptor matches the product and setting in the record.

J9260 vs J8611: what is the difference?

Both are HCPCS Level II codes whose descriptor names methotrexate. What sets J8611 apart: Jylamvo from Shorla Oncology Inc.; oral route; billed per 2.5 mg. J9260 is billed per 50 mg, limit $2.909, MUE 400; J8611 is billed per 2.5 mg, limit $18.264. Report the code whose descriptor matches the product and setting in the record.

Which Medicare coverage articles mention J9260?

1 current Billing and Coding Article in the Medicare Coverage Database lists J9260, covering 4 states: A55639 (Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions).

What diagnosis codes support J9260?

One Medicare billing and coding article lists 299 covered ICD-10-CM codes for J9260, for example J84.111 (Idiopathic interstitial pneumonia, not otherwise specified); J84.112 (Idiopathic pulmonary fibrosis); J84.113 (Idiopathic non-specific interstitial pneumonitis); J84.114 (Acute interstitial pneumonitis); J84.115 (Respiratory bronchiolitis interstitial lung disease). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.